Skip to Content

Join the 'HIV Infection' group to help and get support from people like you.

HIV Infection News

Related terms: Acquired Immune Deficiency Syndrome, Acquired Immunodeficiency Syndrome (AIDS), Acute HIV Infection, Acute Retroviral Syndrome, AIDS, AIDS-Related Complex, Chronic Symptomatic HIV Infection, HIV Infection, Acute, HIV Seroconversion Syndrome, Human Immunodeficiency Virus Infection, Primary HIV Infection, HIV, ARC, Acquired Immunodeficiency Syndrome, HIV/AIDS

HIV Strikes Black Gay Men More, Despite Safer Behaviors

Posted 4 days ago by Drugs.com

THURSDAY, Dec. 6, 2018 – Young black gay men are 16 times more likely to have HIV than whites, even though they have fewer partners, have less unsafe sex, and get tested for HIV more often, a new study shows. "Our study illuminates how HIV disparities emerge from complex social and sexual networks and inequalities in access to medical care for those who are HIV-positive," said senior study ...

Influential U.S. Panel Backs PrEP HIV-Prevention Pills

Posted 20 Nov 2018 by Drugs.com

TUESDAY, Nov. 20, 2018 – For the first time, a highly influential panel of experts says doctors should offer a daily pill to prevent HIV transmission to people who are at high risk for infection with the AIDS-causing virus. This treatment is called pre-exposure prophylaxis – PrEP for short – and it has been shown to be highly effective at preventing HIV's spread, concluded the U.S. Preventive ...

When Meds Suppress HIV, Odds of Sexual Transmission Near Zero: Review

Posted 19 Nov 2018 by Drugs.com

MONDAY, Nov. 19, 2018 – When someone with HIV has the virus suppressed with medication, there is virtually no chance of passing it on to sex partners, a new review concludes. The Public Health Agency of Canada pulled together studies from the last decade looking at the risk of HIV transmission among partners where one person is HIV-positive and one is not. It found there were no cases of ...

Vaginal Ring That Targets Pregnancy, HIV Seems Safe: Study

Posted 26 Oct 2018 by Drugs.com

FRIDAY, Oct. 26, 2018 – An experimental vaginal ring meant to prevent pregnancy and HIV looks safe, according to an early stage study. The dual-purpose ring releases the antiretroviral drug dapivirine and the contraceptive hormone levonorgestrel, said researchers led by Dr. Sharon Achilles, of the University of Pittsburgh School of Medicine. "We are very encouraged by our findings in this ...

Antiviral Med Fuels Rapid Decline in New HIV Infections in Gay Men: Study

Posted 18 Oct 2018 by Drugs.com

THURSDAY, Oct. 18, 2018 – Giving antiviral medications to gay men without HIV led to a 25 percent reduction in new infections of the AIDS-causing virus, a new study shows. Researchers followed 3,700 gay men who were given what's known as pre-exposure prophylaxis (PrEP) under a program in New South Wales, Australia. The regimen generally involves taking a daily pill. Most followed the regimen. ...

New Therapy May Control HIV Without Daily Pills

Posted 26 Sep 2018 by Drugs.com

WEDNESDAY, Sept. 26, 2018 – A combination of two HIV-fighting antibodies can suppress the virus in some patients, even after they stop standard drugs, a preliminary trial has shown. Researchers found that among 11 HIV patients given the antibody combo, nine maintained complete suppression of the virus after going off their medication regimen. The benefit typically lasted about five months. The ...

FDA Approves Merck’s Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) for the Treatment of HIV-1 in Appropriate Patients

Posted 6 Sep 2018 by Drugs.com

KENILWORTH, N.J.--(BUSINESS WIRE) August 30, 2018 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Delstrigo, a once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg) for the treatment of HIV-1 infection in adult ...

FDA Approves Merck’s Pifeltro (doravirine) for the Treatment of HIV-1 in Appropriate Patients

Posted 1 Sep 2018 by Drugs.com

KENILWORTH, N.J.--(BUSINESS WIRE) August 30, 2018 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Pifeltro (doravirine, 100 mg), a new non-nucleoside reverse transcriptase inhibitor (NNRTI) to be administered in combination with other antiretroviral medicines. Pifeltro is indicated for the ...

Newer HIV Therapies Yield Big Gains But Racial Gaps Persist

Posted 21 Aug 2018 by Drugs.com

TUESDAY, Aug. 21, 2018 – Improved treatment has nearly tripled viral suppression rates among HIV patients in the United States over the past two decades, researchers report. But viral suppression rates remain lower among young people and black Americans, the researchers add. About 1.2 million U.S. adults have HIV, the virus that causes AIDS. Achieving and maintaining suppression of the virus is ...

New Drug of Last Resort, Ibalizumab, Tackles Resistant HIV

Posted 16 Aug 2018 by Drugs.com

THURSDAY, Aug. 16, 2018 – HIV, the virus that causes AIDS, is typically a manageable infection, but medications that keep the virus at bay don't work for everyone. Now, researchers have developed a new medication to help them. The U.S. Food and Drug Administration approved the drug – ibalizumab (Trogarzo) – in March. Phase 3 trial results were published in the Aug. 16 issue of the New England ...

HIV Doubles Heart Disease Risk

Posted 30 Jul 2018 by Drugs.com

MONDAY, July 30, 2018 – People with HIV are twice as likely to develop heart disease than those without the AIDS-causing virus, British researchers report. Their review of studies from 153 countries also found that HIV-associated heart disease has more than tripled in the past 20 years, as more people with HIV live longer. More than two-thirds of HIV-associated heart disease occurs in ...

FDA Approves Symtuza (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection

Posted 18 Jul 2018 by Drugs.com

TITUSVILLE, N.J, JULY 17, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved Symtuza (darunavir, cobicistat, emtricitabine and tenofovir alafenamide - D/C/F/TAF), the first and only complete, darunavir-based single-tablet regimen (STR) for the treatment of human immunodeficiency virus type 1 (HIV-1) in t ...

Antiviral Treatments Reduce Cancer Risk for HIV Patients

Posted 11 Jun 2018 by Drugs.com

MONDAY, June 11, 2018 – Long-term antiviral treatment cuts the risk of cancer in HIV patients as they age, a new study says. People with HIV are at increased risk for both AIDS-related cancers (Kaposi sarcoma, non-Hodgkin lymphoma or invasive cervical cancer) and non-AIDS-related cancers (lung and larynx cancer, melanoma and leukemia). Antiretroviral therapy (ART) is a major part of HIV ...

Human Trials Set for Experimental HIV Vaccine

Posted 6 Jun 2018 by Drugs.com

WEDNESDAY, June 6, 2018 – An experimental HIV vaccine protected animals from dozens of strains of HIV. And a human trial of the vaccine is expected to begin in the second half of 2019, according to U.S. researchers. The vaccine targets a vulnerable site on HIV – the virus that causes AIDS – and triggered antibody production in mice, guinea pigs and monkeys, according to researchers with the ...

FDA Medwatch Alert: Juluca, Tivicay, Triumeq (dolutegravir): FDA to Evaluate - Potential Risk of Neural Tube Birth Defects

Posted 20 May 2018 by Drugs.com

ISSUE: Serious cases of neural tube birth defects involving the brain, spine, and spinal cord have been reported in babies born to women treated with dolutegravir used to treat human immunodeficiency virus (HIV). Preliminary results from an ongoing observational study in Botswana found that women who received dolutegravir at the time of becoming pregnant or early in the first trimester appear to ...

Page 1 2 3 ... Next

Ask a Question

Further Information

Related Condition Support Groups

Pre-Exposure Prophylaxis, Viral Infection

Related Drug Support Groups

Atripla, Truvada, Genvoya, Stribild, lamivudine, tenofovir, Viread, Trogarzo, Prezista, view more... Symfi, Odefsey, doravirine, Triumeq, Pifeltro, Descovy, Complera, Symfi Lo, efavirenz, Cimduo, Biktarvy, Intelence, cobicistat, Delstrigo, Carimune, doravirine / lamivudine / tenofovir, Sustiva, Epivir, Reyataz, Norvir, Edurant, Juluca, Symtuza, Tivicay, darunavir, emtricitabine, immune globulin intravenous, ritonavir, Evotaz, Prezcobix, Dutrebis, Epzicom, Panglobulin NF, Retrovir, Flebogamma, Selzentry, Hivid, Aptivus, Zerit, Invirase, Fortovase, Tybost, Sandoglobulin, Gammagard S / D, Octagam, Gammar IV, Gammaplex, Gamimune, Isentress, Viramune, Telzir, Zerit XR, Vitekta, Viramune XR, Iveegam En, Panglobulin, Gamimune N 10%, Gamimune N 5%, Polygam S / D, Gammar-P IV, Venoglobulin-S 10%, Venoglobulin-S 5%, Carimune NF, abacavir, Viracept, nelfinavir, rilpivirine, emtricitabine / nelfinavir / tenofovir, emtricitabine / lopinavir / ritonavir / tenofovir, etravirine, calanolide a, raltegravir, zidovudine, zalcitabine, tipranavir, stavudine, saquinavir, nevirapine, maraviroc, cobicistat / elvitegravir / emtricitabine / tenofovir, lopinavir / ritonavir, lamivudine / zidovudine, indinavir, fosamprenavir, enfuvirtide, emtricitabine / tenofovir, efavirenz / emtricitabine / tenofovir, didanosine, delavirdine, atazanavir, amprenavir, abacavir / lamivudine / zidovudine, emtricitabine / rilpivirine / tenofovir, dolutegravir, Kaletra, lamivudine / nevirapine / zidovudine, Combivir, Epivir-HBV, Crixivan, abacavir / lamivudine, Fuzeon, Emtriva, Videx EC, Videx, Rescriptor, Agenerase, Ziagen, Trizivir, cobicistat / darunavir / emtricitabine / tenofovir alafenamide, abacavir / dolutegravir / lamivudine, ibalizumab, lamivudine / tenofovir, efavirenz / lamivudine / tenofovir, bictegravir / emtricitabine / tenofovir alafenamide, dolutegravir / rilpivirine, emtricitabine / tenofovir alafenamide, emtricitabine / rilpivirine / tenofovir alafenamide, cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide, lamivudine / raltegravir, cobicistat / darunavir, atazanavir / cobicistat, elvitegravir, Lexiva